HC Wainwright started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Tuesday, AnalystRatings.com reports. The brokerage issued a buy rating and a $28.00 target price on the stock.
“Our price target is derived from a market value of the firm at $81M, which includes a discounted cash flow-based asset value for prexigebersen (BP1001), using a 15% discount rate and 1% terminal growth rate, and assuming 2.9M shares outstanding at the end of 2Q20. Probability of success ascribed is 40%, based solely on future U.S. sales of prexigebersen in treatment of AML and MDS.”,” HC Wainwright’s analyst wrote.
NASDAQ:BPTH opened at $13.87 on Tuesday. Bio-Path has a twelve month low of $1.61 and a twelve month high of $73.52. The firm’s 50-day simple moving average is $13.55. The company has a market cap of $42.47 million, a price-to-earnings ratio of -0.96 and a beta of 3.24.
A hedge fund recently bought a new stake in Bio-Path stock. Virtu Financial LLC acquired a new position in shares of Bio-Path Holdings Inc (NASDAQ:BPTH) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 16,461 shares of the company’s stock, valued at approximately $336,000. Virtu Financial LLC owned about 0.66% of Bio-Path at the end of the most recent quarter. Institutional investors and hedge funds own 10.77% of the company’s stock.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading: P/E Growth (PEG)
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.